Conference report on public health and clinical guidelines for anthrax

Emerging Infectious Diseases

Volumn 14, Issue 4, 2008, Pages

  Stern, Eric Jacob ^a   Uhde, Kristin Broome ^a   Shadomy, Sean Vincent ^a   Messonnier, Nancy ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTHRAX; ANTIMICROBIAL THERAPY; BACTEREMIA; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; INFECTION PREVENTION; MENINGITIS; PRACTICE GUIDELINE; PROPHYLAXIS; PUBLIC HEALTH SERVICE; TREATMENT DURATION;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BACTEREMIA; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOGLOBULINS; INHALATION EXPOSURE; MENINGITIS, BACTERIAL; PNEUMONIA, BACTERIAL; PUBLIC HEALTH; SKIN DISEASES, BACTERIAL; TIME FACTORS;

EID: 42149131530     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1404.070969     Document Type: Conference Paper

References (40)

1. Bell DM, Kozarsky PE, Stephens DS. Conference Summary: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002;8:222-5.
2. Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007;44:968-71.
3. Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Resnitz EA, Butler JC, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002;8:1019-28.
4. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis. 2002;8:1124-32.
5. CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2002;51:1024-6.
6. Centers for Disease Control and Prevention. Responding to detection of aerosolized Bacillus anthracis by autonomous detection systems in the workplace. MMWR Morb Mortal Wkly Rep. 2004;53(RR07):1-12.
7. Doganay M, Aydin N. Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis. 1991;23:333-5.
8. Lightfoot N, Scott R, Turnbull B. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull. 1990;68 (Special Suppl):95-8.
9. Turnbull PC, Sirianni NM, LeBron CI, Samaan MN, Sutton FN, Reyes AE, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol. 2004;42:3626-34.
10. Chen Y, Succi J, Tenover FC, Koehler TM. β-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. J Bacteriol. 2003;185:823-30.
11. Materon IC, Queenan AM, Koehler TM, Bush K, Palzkill T. Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrob Agents Chemother. 2003;47:2040-2.
12. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909-19.
13. Athamna A, Athamna M, Abu-Rashed N, Medlej B, Bast DJ, Rubinstein E. Selection of Bacillus anthracis isolates resistant to antibiotics. J Antimicrob Chemother. 2004;54:424-8.
14. Price LB, Vogler A, Pearson T, Busch JD, Schupp JM, Keim P. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother. 2003;47:2362-5.
15. Choe CH, Bouhaouala SS, Brook I, Elliot TB, Knudson GB. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob Agents Chemother. 2000;44:1766.
16. Brook I, Elliott TB, Pryor HI, Sautter TE, Gnade BT, Thaker JH, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001;18:559-62.
17. Friedlander AM, Welkos SL, Pitt ML, Ezzell JW, Worsham PL, Rose KJ, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-43.
18. Department of Health and Human Services. Food and Drug Administration. Prescription Drug Products: Doxycycline and penicillin G procaine administration for inhalational anthrax (postexposure). Fed Register. 2001;66(213)55679-82.
19. Davis H, McGoodwin E, Reed TG. Anaphylactoid reactions reported after treatment wth ciprofloxacin. Ann Intern Med. 1989;111:1041-3.
20. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol. 1997;133:1224-30.
21. Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, et al. Serious adverse events among participants in the Centers for Disease Control and Prevention's anthrax vaccine and antimicrobial availability program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis. 2003;37:905-11.
22. Ortho-McNeil Pharmaceutical. Product insert, Levaquin (Levofloxacin) tablets, 2004.
23. Weingartner L, Sitka U, Patsch R, Thiemann HH, Bromme W, Richter I. Amoxicillin in paediatrics, with special reference to its excretion into bronchial secretion. Int J Clin Pharmacol Ther Toxicol. 1980;18:185-9.
24. Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax. 1994;49:1134-8.
25. Meselson M, Guillemin J, Hugh-Jones M, Langmuir A, Popova I, Shelokov A, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202-8.
26. Vietri NJ, Purcell BK, Lawler JV, Leffel EK, Rico P, Gamble CS, et al. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A. 2006;103:7813-6.
27. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine. 2006;24:3654-60.
28. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax. MMWR Morb Mortal Wkly Rep. 2001;50:941-8.
29. Mayer TA, Morrison A, Bersoff-Matcha S, Druckenbrod G, Murphy C, Howell J, et al. Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001? Clin Infect Dis. 2003;36:1275-83.
30. Hupert N, Bearman G, Mushlin A, Callahan M. Accuracy of screening for inhalational anthrax after a bioterrorist attack. Ann Intern Med. 2003;139:337-45.
31. Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis. 2005;5:287-95.
32. Fritz DL, Jaax NK, Lawrence WB, Davis KJ, Pitt ML, Ezzell JW, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest. 1995;73:691-702.
33. Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis. 2001;7:933-44.
34. Holty JE, Bravata DM, Liu H. R.A. O, K.M. M, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med. 2006;144:270-80.
35. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993;90:2291-4.
36. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. October 2001. MMWR Morb Mortal Wkly Rep. 2001;50:909-19.
37. Brachman P, Gold H, Plotkin S, Fekety F, Werrin M, Ingraham N. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52:632-45.
38. Knudson GB. Treatment of anthrax in man: history and current concepts. Mil Med. 1986;151:71-7.
39. ACOG Committee on Obstetric Practice. ACOG Committee Opinion number 268, February 2002. Management of asymptomatic pregnant or lactating women exposed to anthrax. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2002;99:366-8.
40. Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA. 2002;287:1556-60.